CD40 and pancreatic neoplasm: Agonistic anti-murine TNF receptor such as CP-870893, a fully human anti-CD40 monoclonal antibody, has been assessed in clinical trials with beneficial efficacy in melanoma and pancreatic cancers [213, 214].